Clinical Study Number | 1160.204 |
---|---|
Study Indication | Atrial Fibrillation |
Product | PRADAXA ® |
Generic Name | Dabigatran |
Lab Code | |
Clinical Phase | IV |
Study Title |
Randomised Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral antIcoagulation sTrategy (The RE-CIRCUIT Trial) |
Study Document | Lay summary 1160.204 english |
Clinical Study Number | 1160.186 |
---|---|
Study Indication | Atrial Fibrillation |
Product | PRADAXA ® |
Generic Name | Dabigatran |
Lab Code | |
Clinical Phase | IIIb |
Study Title |
A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110 mg and 150 mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting (RE-DUAL PCI) |
Study Document | Lay summary 1160.186 english |
Download our Policy on Transparency and Publication of Clinical Study Data.Download
Browse our clinical study overview and read study synopses and lay summaries.
Learn about our process of responsible sharing of clinical study data and documents and request access to data and documents.